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The Saccharomyces cerevisiae PRP21 gene product is an integral
component of the prespliceosome
(splicing/spliceosome/U2 small nuclear ribonucleoprotein)
JAIME E. ARENAS AND JOHN N. ABELSON
Division of Biology, 147-75, Califomia Institute of Technology, Pasadena, CA 91125
Contributed by John N. Abelson, April 16, 1993
ABSTRACT In Saceharomyces cerevisiae, the prp2l mu-
tation causes accumulation of unspliced pre-mRNA at the
nonpermissive temperature. We have cloned the PRP21 gene
by complementation of its temperature-sensitive phenotype
and found it to be the same as SPP91, an extragenic suppressor
of the prp9 mutation previously studied in vivo by Chapon and
Legrain [Chapon, C. & Legrain, P. (1992) EMBO J. 11,
3279-3288]. We have analyzed the effects ofthepprp2l mutation
on splicing in vitro and have found that PRP21 is a splicing
factor required for prespliceosome assembly. We also have
analyzed the interaction of PRP21 with splicing complexes
using anti-PRP21 antibodies and found that the RNA compo-
nents of the prespliceosome-U1 and U2 small nuclear RNA
(snRNA) particles and pre-mRNA-are specifically coimmu-
noprecipitated under splicing conditions in the presence of 0.2
M KCI. At higher KCI concentrations, Ul snRNP dissociates
from splicing complexes; nevertheless, U2 snRNA and pre-
mRNA are still efficiently immunoprecipitated. Immunopre-
cipitation of both Ul and U2 snRNA as well as pre-mRNA is
ATP-dependent and requires a pre-mRNA capable of support-
ing prespliceosome assembly. Analysis of the unbound com-
plexes in native gels confirmed that prespliceosomes are spe-
cifically immunoprecipitated by anti-PRP21 antibodies. These
results demonstrate that PRP21 is an integral component of the
prespliceosome and establishes a stable interaction with U2
snRNP and/or pre-mRNA in that complex.
Nuclear pre-mRNA splicing occurs in the spliceosome, a
large multicomponent complex containing Ul, U2, U4, US,
and U6 small nuclear ribonucleoprotein (snRNP) particles, a
numberofnon-snRNPproteinfactors, andpre-mRNA. Splice-
osome assembly is an ordered process that begins with
binding of the U1 snRNP to the 5' end of the intron, forming
a complex known as the commitment complex. Then, U2
snRNP binds to the conserved branch site sequence in an
ATP-dependent manner to form the complex known as the
prespliceosome. Subsequently, U4, U6, and U5 snRNPs are
added to the complex to form the spliceosome. Splicing
proceeds in two cleavage/ligation steps. In the first step, the
5' splice site is cleaved concomitant with the formation of a
2'-5' phosphodiester bond between the 5' end of the intron
and a specific adenosine residue in the branch site sequence,
producing a lariat molecule containing the intron and second
exon. The second step involves the cleavage of the 3' splice
site and ligation of the two exons to produce mature mRNA
(for review see refs. 1-4 and references therein).
Our current understanding of the splicing mechanism and
its regulation comes largely from the identification and char-
acterization of the factors involved. The generation of tem-
perature-sensitive (ts) strains and other genetic approaches in
Saccharomyces cerevisiae has greatly simplified the task of
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identification and cloning of a large number of genes that
affect pre-mRNA processing (PRP genes; reviewed in refs. 1
and 4).
Yeast strains carrying the prp2l mutation piesent a ts
splicing defect causing accumulation ofunspliced pre-mRNA
at the nonpermissive temperature (5). We have cloned the
PRP21 gene and performed in vitro studies to investigate the
role ofPRP21 in the splicing process. Our results indicate that
PRP21 is required for prespliceosome assembly and that it
interacts with U2 snRNP and/or pre-mRNA in the presplice-
osome.
MATERIALS AND METHODS
Yeast Strains and Extracts. The wild-type (wt) yeast strains
used in these studies were SS330 (MATa, ade2-101, his3A200,
tyri, ura3-52) and EJ101 (MATa, trpl, prol-126, prbl-112,
pep4-3, prcl-126). The prp2l strain was previously selected
from a bank of ts mutants generated by in vivo ethyl meth-
anesulfonate mutagenesis of SS330 (5). Yeast splicing ex-
tracts were prepared as described (6). Heat inactivation was
performed by heating extract aliquots at 40°C for 6-7.5 min
just before being used in splicing reactions.
Cloning and Complementation. The PRP21 gene was iso-
lated by transformation of the prp2l strain with a pYCP50
yeast genomic library (7). Plasmid DNA recovered from two
transformants growing at 37°C was cut with various restric-
tion enzymes, and the fragments were subcloned into the
pPHY18 yeast CEN plasmid (8), transformed into the prp2l
strain, and tested for growth at 37°C. All yeast transforma-
tions were carried out by the lithium acetate protocol (9). A
2-kilobase (kb) HindIII fragment* was sequenced by using a
dideoxy sequencing kit as suggested by the manufacturer
(United States Biochemical). The PRP21 gene was contained
in a smaller 1.1-kb HindIII-Xho I fragment that comple-
mented the prp2l growth defect.
Generation of Anti-PRP21 Antiserum. By using standard
polymerase chain reaction (PCR) and cloning techniques, the
PRP21 open reading frame was subcloned into the Nde I site
ofpETila (Novagen, Madison, WI) for expression under the
control ofT7 polymerase in Escherichia coli (10). Expression
of PRP21 in this system yielded a 33-kDa polypeptide in the
form ofinsoluble inclusion bodies in quantities that amounted
to about 30-50% of the total protein. PRP21 inclusion bodies
were purified as described (11). PRP21 was further purified
from solubilized inclusion bodies by preparative polyacryl-
amide/SDS gel electrophoresis. Rabbit antiserum against the
electrophoretically pure PRP21 protein was prepared by
Cocalico Biologicals (Reamstown, PA).
Abbreviations: ts, temperature sensitive; PAS, protein A-Sepharose;
PAS-Ab, PAS with bound antibody; snRNP, small nuclear ribonu-
cleoprotein; wt, wild type.
*The complete sequence of the HindIII fragment determined in this
work has been deposited in the GenBank data base (accession no.
L07744).
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Immunoaffinity purified anti-PRP21 antibodies were pre-
pared from rabbit antiserum by acid elution of the antibodies
bound to Immobilon-P membranes coated with PRP21 es-
sentially as described (12).
Splicing Assay and Native Gel Electrophoresis. In vitro
splicing reactions were essentially as described (13). Reac-
tions containing 40-50% extract were incubated at 15°C and
stopped by addition of a buffer containing heparin prior to
native gel electrophoresis (14); however, the electrophoresis
procedure was modified to increase resolution. Samples were
loaded on 3% polyacrylamide gels (24 x 18 x 0.1 cm; 20:1
acrylamide/methylenebisacrylamide) in TAE buffer (40 mM
Tris acetate/1 mM EDTA, pH 7.2 at 20°C) and run at 4°C for
6-8 hr at 200 V with circulating buffer.
Immunoprecipitations. Protein A-Sepharose suspension
(PAS, 150 ul; Sigma) was washed twice with 1 ml of NET
buffer (50 mM Tris HCl, pH 7.5/0.1% Nonidet P-40/1 mM
EDTA/0.02% sodium azide) containing 500 mM KCI (NET-
500) and was resuspended in a final volume of 150 ,ul in NET
containing 150mM KCI (NET-150). Then, 500 ,ul ofNET-500
and 200 ,l of rabbit antiserum or purified anti-PRP21 anti-
bodies were added and mixed gently at 4°C for 1-4 hr.
Finally, the PAS beads with bound antibodies (PAS-Ab) were
washed three times with 1 ml of NET-500, once with NET-
150, and resuspended in 300-,lI final suspension volume in
NET-1S0.
For direct immunoprecipitations from extracts, 20-,l4 ali-
quots of PAS-Ab suspension in 300 Al ofNET containing the
appropriate concentration of KCl (NET-KCI) were supple-
mented with 1 mM dithiothreitol and 0.5 units of RNasin per
/4. Then, 20 ,ul of yeast extract was added and mixed for 1 hr
at 4°C. PAS-Ab beads were washed twice with 1 ml of the
corresponding NET-KCl and once with NET for 5 min at 4°C
each time and finally were resuspended in 100 /4 of NET
supplemented with 5 mM EDTA, 0.1% SDS, 10 ,ug of E. coli
tRNA per ml, and 10 jig of proteinase-K per ml. After 10 min
at 37°C, the suspension was extracted with phenol/chloroform
in TE buffer (10 mM Tris HCl/l mM EDTA, pH 7.4) and
precipitated with ethanol.
For immunoprecipitation under splicing conditions, 20-,ul
splicing reaction mixtures containing 100 fmol of unlabeled
actin pre-mRNA were incubated 10-60 min at 15°C, and the
reactions were stopped in ice by addition of 80 ,il of SPL
buffer (50 mM K2HPO4, pH 7.0/2.5 mM MgCl2/1 mM
dithiothreitol) containing 5 mg of heparin (Sigma H-3125) per
ml and the indicated concentration of KCI. After addition of
heparin, splicing complexes are stable for several hours at
4°C (J.E.A., unpublished data). Then, 20 ,ul of PAS-Ab
suspension in the corresponding SPL-KCI buffer was added
and mixed at 4°C for 30-120 min. The beads were washed
twice with the corresponding SPL-KCI buffer and transferred
into a new tube. Finally, the bound RNA was extracted as
above. It is critical to transfer the beads into a new tube
before extraction because, under these conditions, signifi-
cant amounts of snRNPs, especially Ul snRNP and U5
snRNP, stick to the tube walls. However, no snRNPs bound
to PAS without bound antibodies at any concentration ofKCI
(data not shown).
For analysis of unbound splicing complexes, a 50-,ul splic-
ing reaction with 50 fmol of actin pre-mRNA labeled with
[a-32P]UTP was stopped in ice with 10 ,ul of 60 mM K2HPO4
(pH 7.0) containing 3 mM MgCl2, 3% PEG, 8% (wt/vol)
glycerol, 25 mg of heparin per ml, and 150 mM KCI. Then
15-,lI aliquots were mixed with 10 /l ofPAS-Ab in SPL buffer
containing 150 mM KCl. After mixing for 30 min at 4°C, the
splicing complexes remaining in the supernatant were ana-
lyzed by native gel electrophoresis. The beads were washed,
and the bound splicing products were extracted as above and
analyzed in 8% polyacrylamide (29:1 acrylamide/methylene-
bisacrylamide)/7 M urea gels.
Northern Blots. Immunoprecipitated RNA from reactions
containing unlabeled pre-mRNA was resolved in 8% poly-
acrylamide/7 M urea gels and transferred to GeneScreen
membrane (NEN). The membranes were probed as described
(15) with a mixture of snRNA probes generated by PCR from
plasmids carrying yeast genes for snRNA or actin and were
labeled with [a-32P]dATP by using the random priming syn-
thesis kit from Boehringer Mannheim.
RESULTS AND DISCUSSION
Cloning and Sequence of PRP21. The PRP21 gene was
isolated by complementation of the ts growth defect of the
prp2l strain with a genomic yeast library. Sequence analysis
of a DNA fragment complementing the growth defect re-
vealed an open reading frame encoding a 280-amino acid
polypeptide (PRP21) with a predicted molecular mass of
33-kDa. The nucleotide sequence of PRP21 is the same as
SPP91, a gene identified as a second site suppressor (spp91)
of the growth defect of a prp9 mutant (16).
PRP21 Is Required for Prespliceosome Assembly. It was
previously shown in vivo that the prp2l mutation causes
accumulation of unspliced pre-mRNA at a nonpermissive
temperature, suggesting that PRP21 is involved in an early
step of the splicing process (5). To define the role of PRP21
in splicing, we have established conditions for heat inactiva-
tion of extracts prepared from the prp2l strain grown at the
permissive temperature (prp2l extract). We found that prp2l
extracts exhibited normal splicing activity. However, when
the prp2l extract was preheated at 40°C for as little as 6 min
(Aprp2l extract), the splicing activity was abolished while the
wt extract retained full activity after similar treatment (Fig.
1A, lanes a-f). Some residual activity was often observed in
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FIG. 1. Heat-inactivation in vitro. wt and prp2l extracts or the
40P3 fraction were heated at 40°C and then tested for splicing activity
and spliceosome formation. Splicing reactions containing labeled
actin pre-mRNA were incubated at 15°C for 60 min. (A) Denaturing
gel electrophoresis of splicing products from reactions containing wt
extracts preheated for 0, 6, or 15 min (lanes a-c, respectively); prp2l
extracts preheated for 0, 6, or 15 min (lanes d-f); and 40P3 fraction
preheated 0, 6, or 15 min (lanes g-i). Complementation is shown by
reactions containing prp2l extract preheated for 6 min in addition to
40P3 fraction preheated for 0, 6, or 15 min (lanes j-l). The products
of the splicing reaction are represented schematically. Exons are
shown as boxes, and the intron is represented by a line; circles
represent RNA lariat forms. (B) Splicing complexes formed in
reactions containing untreated or preheated extracts as in A were
resolved in native gels. Lanes: a-c, wt extract preheated 0, 7.5, or 15
min, respectively; d-f, prp2l extract preheated for 0, 7.5, or 15 min.
Complex A contains U2, U5, U4, and U6 snRNAs in addition to
pre-mRNA and splicing intermediates. Complex B contains pre-
mRNA and U2 snRNA. Ul snRNA is not detected in this gel system
(14); nonetheless complexes A and B are representative of spliceo-
somes and prespliceosomes, respectively. Complex C corresponds
to heterogeneous nonspecific complexes.
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Aprp2J extracts heated for 6-7 min and could be eliminated
by extending the heat treatment by 1 or 2 additional min.
However, longer treatment also resulted in some reduction of
the splicing activity of wt extracts (Fig. 1A, lane c). Splicing
is blocked at the first step of the reaction in Aprp2l extracts,
indicating that PRP21 is a splicing factor required before 5'
splice site cleavage. Furthermore, PRP21 appears to be an
exchangeable factor because the splicing activity in the
Aprp2J extract could be restored by complementation with an
inactive 40% saturation ammonium sulfate pellet fraction
(40P3) prepared from wt extract (17). 40P3 exhibited com-
plementing activity even after heat treatment for 15 min at
40°C (Fig. 1A, lanes j-l).
Mutations blocking the first step of splicing may either
prevent spliceosome formation or allow the assembly of a
nonfunctional spliceosome. To examine the role of PRP21 in
spliceosome assembly, we stopped the splicing reactions
with heparin and analyzed the splicing complexes formed by
native gel electrophoresis as described (14). Neither pre-
spliceosomes or spliceosomes formed in reactions with
Aprp2l extracts (complexes B and A, respectively; Fig. 1B)
indicating that PRP21 is required for the assembly of pre-
spliceosomes.
PRP21 Is a Component of the Prespliceosome. Contrary to
mammalian cells, the snRNPs in Saccharomyces cerevisiae
are found in low abundance, making their biochemical char-
acterization more difficult. Thus, little is known about their
protein composition. Through the use of specific antibodies,
some yeast splicing factors have been found to be tightly
associated with snRNPs. By this criterion, PRP4 and PRP6
are U4/U6 snRNP proteins (18-20), while PRP8 is a U5
snRNP protein (21, 22). We have studied the interaction of
PRP21 with snRNPs using rabbit antiserum raised against
gel-purified PRP21 protein produced in E. coli. We attempted
direct immunoprecipitation of snRNPs from wt extracts
diluted in NET-KCI buffer and found that no significant
amounts of any snRNA could be specifically immunoprecip-
itated under these conditions, with KCI concentrations rang-
ing from 0.05 M to 1 M, suggesting that PRP21 is not tightly
associated to snRNPs. However, we can not rule out the
possibility that PRP21 might be an snRNP protein whose
antigenic epitopes are not accessible to antibodies under the
conditions used.
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The requirement for PRP21 in early spliceosome assembly
suggests that it may interact at least transiently with spliceo-
somal components. To address this question, we attempted
immunoprecipitation of splicing complexes under splicing
conditions. Splicing reactions containing unlabeled pre-
mRNA were stopped with heparin, and immunoprecipitation
was then carried out in splicing buffer as described in
Materials and Methods. When anti-PRP21 antibodies were
used, efficient and specific coimmunoprecipitation of the
RNA components of the prespliceosome-Ul snRNA, U2
snRNA, and pre-mRNA-was observed in the presence of
200mM KCI. In contrast, when pre-mRNA was omitted from
the splicing reaction or when control antibodies from preim-
mune serum was used, none of these RNAs was immuno-
precipitated at KCI concentrations higher than 50 mM (Fig.
2 A and B). Furthermore, a correlation between the relative
amounts of Ul snRNA, U2 snRNA, and pre-mRNA immu-
noprecipitated was apparent, suggesting that all three RNAs
are part ofthe same complex, most likely the prespliceosome
(Figs. 2 and 3; also data not shown).
After the commitment complex is formed by Ul snRNP
binding to the 5' splice site, ATP is required for binding ofU2
snRNP to the branch site to form the prespliceosome. We
have tested the possibility that anti-PRP21 antisera could
immunoprecipitate prespliceosomes by assaying both ATP
dependence and pre-mRNA sequence requirements for im-
munoprecipitation of all three components. As expected,
when ATP was omitted from the splicing reaction, immuno-
precipitation of both Ul and U2 snRNAs as well as pre-
mRNA was reduced to background levels (Fig. 2 C and D).
Identical results were obtained with antibodies from crude
anti-PRP21 antiserum or with immunoaffinity-purified anti-
PRP21 antibodies (data not shown). Phosphor-imaging quan-
tification of the experiments shown in Fig. 2 showed that at
200mM KCl, the immunoprecipitation ofUl and U2 snRNAs
was stimulated 50- and 70-fold, respectively, by the addition
of pre-mRNA to the reactions, whereas addition of ATP
stimulated immunoprecipitation of Ul snRNA, U2 snRNA,
and pre-mRNA by 19-, 14-, and 37-fold, respectively. Immu-
noprecipitation of small amounts of prespliceosome compo-
nents in the absence ofATP or pre-mRNA is likely due to the
presence of endogenous ATP and pre-mRNA in the extract.
It has been shown that yeast spliceosomal complexes do
not form on actin pre-mRNA mutants carrying either the 5'
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FIG. 2. Immunoprecipitation of splicing complexes. (A and B) Standard splicing reaction mixtures contained wt extract, ATP, and 100 fmol
of unlabeled actin pre-mRNA (lanes + pre-mRNA) or no added pre-mRNA (lanes labeled No pre-mRNA). After incubation at 15°C, the reaction
was stopped with heparin, and immunoprecipitation was carried out under splicing conditions with preimmune antibodies (lanes pre-imm) or
anti-PRP21 antibodies (lanes a-PRP21) as described in the presence of KCI at 0.05 M (lanes a), 0.2 M (lanes b), 0.4 M (lanes c), and 0.6 M (lanes
d). Bound RNA was extracted and analyzed by Northern blot by probing successively with a mixture of U snRNA probes (A) and with actin
pre-mRNA probe (B). Pre-mRNA was the only RNA species detected with the pre-mRNA probe; thus, only that portion of the blot is shown.
(C and D) Immunoprecipitations from reactions with wt extract, pre-mRNA, and ATP as above (lanes +ATP) or without ATP (lanes -ATP).
Immunoprecipitations were in the presence of KCI as above with anti-PRP21 antibodies.
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FIG. 3. Effect ofpre-mRNA sequence in immunoprecipitation of
prespliceosome components. Splicing reactions were as in Fig. 2 with
100 fmol of one of several actin pre-mRNA mutants. Each of the
mutant pre-mRNAs also contains a 6-nucleotide deletion (A6) that
eliminates a cryptic branch site in the intron. The A6 pre-mRNA
behaves as its wt counterpart in splicing reactions (23). Lanes: a, wt
pre-mRNA; b, A6 pre-mRNA; c, no pre-mRNA; d, A6-A1; e, A6-C1;
f, A6-A257; g, A6-C259; h, A6-C303/C305. A6-A1 and A6-C1 are
mutations of the guanosine at position 1 of the intron; A6-A257 and
A6-C259 are mutations in the invariable TACTAAC branch point
sequence; A6-C303/C305 is a double mutation ofthe 3' splice site. All
immunoprecipitations were carried out in the presence of 0.2 M KCl
and the bound RNA analyzed as in Fig. 2.
splice site mutations Al or Cl or the branch site mutations
A257 and C259. However, spliceosomes can form on a
pre-mRNA carrying a 3' splice site double-mutation C303/
C305 (14, 23, 24). We performed immunoprecipitation exper-
iments using these mutant actin pre-mRNAs and found that
mutations at either the 5' splice site or the branch site do not
support immunoprecipitation of prespliceosomal RNAs to
levels higher than those found when no pre-mRNA is added.
In contrast, significant amounts of Ul snRNA, U2 snRNA,
and pre-mRNA are immunoprecipitated when wt or 3' splice
site mutant pre-mRNA are added (Fig. 3). These results
demonstrate that coprecipitation of Ul snRNA, U2 snRNA,
and pre-mRNA requires the assembly of splicing complexes
and strongly suggest that immunoprecipitation of these
RNAs is due to specific recognition of prespliceosomes by
anti-PRP21 antibodies.
Using labeled actin pre-mRNA, we have further investi-
gated the identity of the immunoprecipitated complexes by
resolving the unbound splicing complexes in native gels (Fig.
4A). Prespliceosomes (complex B) are quantitatively re-
moved from splicing mixtures treated with anti-PRP21 anti-
bodies, while spliceosomes (complex A) remained in the
supernatant. Analysis of the splicing products immunopre-
cipitated shows that only pre-mRNA and not splicing inter-
mediates or mRNA are immunoprecipitated (Fig. 4B). To-
gether, these results show that the anti-PRP21 antibodies can
indeed immunoprecipitate prespliceosomes and that PRP21
is an integral component of that complex.
Although splicing complexes are stable for extended peri-
ods of time under the conditions used for immunoprecipita-
tions, in none of our experiments were we able to detect
splicing intermediates, excised introns, or mRNA, even
when splicing proceeded for 1 hr before immunoprecipitation
(Fig. 4B and data not shown), indicating that spliceosomes
that have proceeded beyond the first step of splicing are not
immunoprecipitated by anti-PRP21 antibodies. Furthermore,
it is unlikely that immunoprecipitation of small amounts of
pre-mRNA as well as U2, US, and U6 snRNAs at high KCI
concentrations represents mature spliceosomes, since U5
and U6 snRNA precipitation was not consistently observed
(compare Fig. 2 A and C) and similar immunoprecipitation
FIG. 4. Analysis of unbound splicing complexes. Standard splic-
ing reactions containing 10 fmol of radiolabeled pre-mRNA were
stopped with heparin, and splicing complexes were immunoprecip-
itated in the presence of 0.15 M KCI as described in text. (A)
Autoradiography of the unbound splicing complexes separated by
native gel electrophoresis of the supernatant after immunoprecipi-
tation with PAS with no antibodies (lane 1), PAS with preimmune
antibodies (lane 2), PAS with purified anti-PRP21 antibodies (lane 3),
and no PAS or antibodies (lane 4). (B) Autoradiography of the bound
splicing products from the same experiment resolved by denaturing
gel electrophoresis. Lanes: 1, total RNA no PAS or antibodies; 2,
PAS with no antibodies; 3, PAS with preimmune antibodies; 4, PAS
with purified anti-PRP21 antibodies. Note that the lane numbers in
B do not coincide with those in A.
was also observed in reactions in which ATP or pre-mRNA
had been omitted (data not shown). Accordingly, our native
gel analysis of the unbound complexes after immunoprecip-
itation also indicates that spliceosomes are not recognized by
anti-PRP21 antibodies. Similarly, failure to immunoprecipi-
tate pre-mRNA and Ul snRNP when ATP was omitted from
the splicing reaction indicates that anti-PRP21 antibodies do
not recognize commitment complexes. However, we can not
determine at this time whether PRP21 is only transiently
associated with the prespliceosome or if it is also a compo-
nent of other splicing complexes in which the PRP21 epitopes
are not accessible to antibodies. For example, it is conceiv-
able that after addition of the U4, U6, and US snRNPs to the
prespliceosome, PRP21 is no longer accessible to antibodies.
However, it is also possible that PRP21 leaves or becomes
loosely associated with the spliceosome concomitant with the
addition of the U4, U6, and US snRNPs.
PRP21 Is Tightly Associated with U2 snRNP or Pre-mRNA
or Both. We have demonstrated that immunoprecipitation of
U2 snRNA, Ul snRNA, and pre-mRNA in 200 mM KCI is
due to the immunoprecipitation of prespliceosomes. How-
ever, at 400 mM KCI the coprecipitation of these three RNA
species is abolished or drastically reduced. Interestingly, U2
snRNA and pre-mRNA are still efficiently immunoprecipi-
tated at 300 mM KCI, whereas Ul snRNA is no longer
present in the immunoprecipitate (Fig. 5). This observation
indicates that binding of PRP21 to Ul snRNP is not required
for coprecipitation of U2 snRNP and pre-mRNA and that the
Ul snRNP can be selectively removed from the prespliceo-
some, leaving a stable U2 snRNP-pre-mRNA complex con-
taining PRP21. This result is consistent with previous obser-
vations showing that the Ul snRNP is loosely associated
while U2 snRNP maintains a stable interaction with pre-
mRNA (14, 25-27). Therefore, PRP21 must interact with the
U2 snRNP, the pre-mRNA, or both components of the
A a b c d e f g h
Proc. NatL Acad Sci. USA 90 (1993)
I --
"-,
Proc. Natl. Acad. Sci. USA 90 (1993) 6775
A pre-imm a-PRP21
a b c d a b c d
-U2
-Ul
-U5L
-U5S
-U4
-U6
B
*t pre-mRNA
FIG. 5. Effect of KCI in immunoprecipitation of prespliceosome
components. Standard splicing reactions containing 100 fmol of un-
labeled pre-mRNA as in Fig. 2 were immunoprecipitated with preim-
mune antibodies (lanes pre-imm) or with immunopurified anti-PRP21
antibodies (lanes aPRP21) in the presence of KCl at 0.15 M (lanes a),
0.3 M (lanes b), 0.5 M (lanes c), or 1 M Qanes d). Immunoprecipitated
RNA was analyzed by Northern blots as in Fig. 2.
prespliceosome. We cannot distinguish whether this is a
direct interaction or whether it occurs through an interaction
with other protein factors. An interaction between U2 snRNP
and PRP21 is also supported by the formation of synthetic
lethals (inviable double mutants) in crosses between prp2l
and strains carrying cold-sensitive mutations in the stem loop
Ila of the U2 snRNA (S. Fischer-Wells and M. Ares, Jr.,
personal communication; S. Ruby and J.N.A., unpublished
data). The stem loop Ila of U2 snRNA has been shown to be
an essential structure involved in U2 snRNP binding to
pre-mRNA (28, 29).
Role of PRP21 in Spliceosome Assembly. Based on our in
vitro observations, we propose that PRP21 plays a role in U2
snRNP binding by establishing a strong interaction with the
U2 snRNP or the pre-mRNA or both, and, thus, becomes an
integral component of the prespliceosome. In yeast, only the
products of the PRP9 and PRP5 genes have previously been
shown to be required for prespliceosome assembly (1, 20, 30).
The commitment complex containing Ul snRNP and pre-
mRNA (31, 32) forms efficiently in heat-inactivated prp9
extracts (20) and in wt extracts immunodepleted with anti-
PRP9 antibodies (P. Legrain, personal communication); how-
ever, PRP9 is required for U2 snRNP binding to the pre-
mRNA. Furthermore, in wt extracts, U2 snRNP is required
for immunoprecipitation of pre-mRNA with an antibody
against epitope-tagged PRP9 under splicing conditions (20).
Those observations bear striking similarity to what we found
with anti-PRP21 antibodies and, thus, suggest that PRP9 may
be required at the same time as PRP21 and also may be a
component of the prespliceosome. This possibility is sup-
ported by the isolation of a PRP21 allele (spp9l) that sup-
presses the prp9 growth defect (16). A direct interaction
between PRP9 and SPP91 has been shown in vivo (P. Legrain,
personal communication). Furthermore, a physical interac-
tion is also suggested from genetic experiments in which
pairwise combinations ofprp2l, prp9, prpll, andprpS exhibit
synergistic lethality (S. Ruby, T.-H. Chang, and J.N.A.,
unpublished data). Thus, the most likely explanation for the
genetic and biochemical results is that PRP9 and PRP21 are
required at the same time for U2 snRNP binding and that
PRP21 and PRP9 interact together with the U2 snRNP or
both. Further in vitro experiments will be necessary to
unequivocally establish the functional relationship between
U2 snRNP, PRP9, and PRP21.
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